| Literature DB >> 22005845 |
Ibrahim Danad1, Pieter G Raijmakers, Yolande E Appelman, Hendrik J Harms, Stefan de Haan, Mijntje L P van den Oever, Cornelis van Kuijk, Cornelis P Allaart, Otto S Hoekstra, Adriaan A Lammertsma, Mark Lubberink, Albert C van Rossum, Paul Knaapen.
Abstract
BACKGROUND: There has been increasing interest in quantitative myocardial blood flow (MBF) imaging over the last years and it is expected to become a routinely used technique in clinical practice. Positron emission tomography (PET) using [(15)O]H(2)O is the established gold standard for quantification of MBF in vivo. A fundamental issue when performing quantitative MBF imaging is to define the limits of MBF in a clinically suitable population. The aims of the present study were to determine the limits of MBF and to determine the relationship among coronary artery disease (CAD) risk factors, gender and MBF in a predominantly symptomatic patient cohort without significant CAD.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22005845 PMCID: PMC3227802 DOI: 10.1007/s00259-011-1956-0
Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN: 1619-7070 Impact factor: 9.236
Baseline patient characteristics according to gender
| Men ( | Women ( |
| |
|---|---|---|---|
| Age (years, mean ± SD) | 52 ± 10 | 55 ± 10 | 0.18 |
| Risk factors for CAD | |||
| BMI (kg·m−2, mean ± SD) | 27 ± 4 | 27 ± 4 | 0.52 |
| Diabetes mellitus, | 11 (22) | 10 (13) | 0.17 |
| Hypertension, | 18 (36) | 33 (42) | 0.48 |
| Hypercholesterolaemia, | 12 (24) | 25 (32) | 0.33 |
| Family history of premature CAD, | 21 (42) | 39 (50) | 0.38 |
| History of smoking, | 19 (38) | 33 (42) | 0.63 |
| Medication, | |||
| Statins | 24 (48) | 39 (50) | 0.83 |
| Beta-blockers | 26 (52) | 48 (62) | 0.29 |
| Aspirin | 28 (56) | 46 (59) | 0.74 |
| ACE inhibitors | 5 (10) | 13 (17) | 0.21 |
| AT-II antagonists | 4 (8) | 14 (18) | 0.09 |
| Calcium antagonists | 9 (18) | 15 (19) | 0.86 |
| Long-acting nitrates | 7 (14) | 8 (10) | 0.52 |
| Reason for referral, | |||
| Typical angina pectoris | 7 (14) | 18 (23) | 0.21 |
| Atypical angina pectoris | 19 (38) | 37 (47) | 0.29 |
| Non-anginal chest pain | 16 (32) | 17 (22) | 0.20 |
| High risk, no chest discomfort | 8 (16) | 6 (8) | 0.14 |
| Pretest likelihood of CAD, | |||
| Low | 10 (20) | 25 (32) | 0.14 |
| Intermediate | 35 (70) | 45 (58) | 0.16 |
| High | 5 (10) | 8 (10) | 0.96 |
Fig. 1Flow chart showing criteria for exclusion of obstructive CAD (ICA invasive coronary angiography, FFR fractional flow reserve, CTCA CT coronary angiography, CACS coronary artery calcium score)
Systemic haemodynamic characteristics of the patients at baseline and during hyperaemia
| Parameter | Men ( | Women ( |
| |
|---|---|---|---|---|
| Heart rate (bpm) | Baseline | 60 ± 8 | 62 ± 9 | 0.19 |
| Hyperaemia | 79 ± 14 | 82 ± 14 | 0.27 | |
|
| <0.001 | <0.001 | ||
| Systolic blood pressure (mmHg) | Baseline | 109 ± 16 | 110 ± 16 | 0.65 |
| Hyperaemia | 113 ± 17 | 114 ± 19 | 0.72 | |
|
| 0.27 | 0.20 | ||
| Diastolic blood pressure (mmHg) | Baseline | 60 ± 10 | 59 ± 7 | 0.93 |
| Hyperaemia | 60 ± 7 | 59 ± 8 | 0.63 | |
|
| 0.39 | 0.60 | ||
| Rate–pressure product (mmHg·min−1) | Baseline | 6,523 ± 1,423 | 6,876 ± 1,551 | 0.20 |
| Hyperaemia | 8,959 ± 2,184 | 9,372 ± 2,370 | 0.33 | |
|
| <0.001 | <0.001 | ||
| Mean arterial pressure (mmHg) | Baseline | 76 ± 11 | 76 ± 9 | 0.85 |
| Hyperaemia | 76 ± 10 | 77 ± 11 | 0.66 | |
|
| 0.90 | 0.64 |
Fig. 2Frequency distributions of global baseline (a) and hyperaemic (b) MBF in the whole study population (a COV 31%, b COV 35%)
Baseline MBF (ml·min−1·g−1) in men and women. Values are means ± SD (range)
| Parameter | Men | Women |
| ||
|---|---|---|---|---|---|
| Globala | 0.91 ± 0.34 (0.54–2.35) | 1.09 ± 0.30 (0.59–2.75) | <0.01 | ||
| Vascular territory | |||||
| Left circumflex artery | 0.91 ± 0.36 (0.54–2.38) | 1.12 ± 0.30 (0.55–2.70) | <0.01 | ||
| Right coronary artery | 0.86 ± 0.32 (0.40–2.33) | 1.03 ± 0.28 (0.55–2.40) | <0.01 | ||
| Left anterior descending artery | 0.97 ± 0.36 (0.57–2.34) | 1.11 ± 0.34 (0.64–3.07) | 0.02 | ||
|
| 0.33 | 0.16 | |||
| Myocardial region | |||||
| Septum | 0.92 ± 0.36 (0.52–2.57) | 1.08 ± 0.33 (0.58–3.02) | 0.01 | ||
| Inferior | 0.84 ± 0.30 (0.35–2.08) | 1.01 ± 0.27 (0.55–2.18)* | <0.01 | ||
| Lateral | 0.92 ± 0.36 (0.54–2.38) | 1.12 ± 0.30 (0.55–2.70) | <0.01 | ||
| Anterior | 1.03 ± 0.39 (0.56–2.45) | 1.18 ± 0.36 (0.71–3.19) | 0.03 | ||
|
| 0.07 | 0.01 | |||
*p < 0.01, inferior vs. anterior wall.
aMean MBF in whole left ventricle
Hyperaemic MBF (ml·min−1·g−1) in men and women. Values are means ± SD (range)
| Parameter | Men | Women |
| ||
|---|---|---|---|---|---|
| Globala | 2.90 ± 0.85 (1.52–5.22) | 3.78 ± 1.27 (1.72–8.15) | <0.001 | ||
| Vascular territory | |||||
| Left circumflex artery | 2.99 ± 0.99 (1.63–6.62) | 3.84 ± 1.23 (1.74–7.89) | <0.001 | ||
| Right coronary artery | 2.83 ± 0.84 (1.43–5.41) | 3.67 ± 1.34 (1.83–8.85) | <0.001 | ||
| Left anterior descending artery | 2.92 ± 0.86 (1.51–5.49) | 3.85 ± 1.35 (1.60–8.38) | <0.001 | ||
|
| 0.67 | 0.61 | |||
| Myocardial region | |||||
| Septum | 2.78 ± 0.78 (1.33–4.70) | 3.76 ± 1.40 (1.71–8.67) | <0.001 | ||
| Inferior | 2.95 ± 1.05 (1.39–7.00) | 3.70 ± 1.30 (1.77–8.05) | <0.01 | ||
| Lateral | 2.99 ± 1.00 (1.59–6.62) | 3.84 ± 1.23 (1.74–7.89) | <0.001 | ||
| Anterior | 2.98 ± 0.98 (1.38–6.31) | 3.92 ± 1.58 (1.65–9.51) | <0.001 | ||
|
| 0.51 | 0.78 | |||
aMean MBF in whole left ventricle
CFR in men and women. Values are means ± SD (range)
| Parameter | Men | Women |
| ||
|---|---|---|---|---|---|
| Globala | 3.42 ± 1.24 (1.55–7.97) | 3.67 ± 1.45 (1.36–9.06) | 0.33 | ||
| Vascular territory | |||||
| Left circumflex artery | 3.52 ± 1.42 (1.64–9.88) | 3.64 ± 1.46 (1.36–9.38) | 0.66 | ||
| Right coronary artery | 3.56 ± 1.39 (1.44–8.93) | 3.77 ± 1.66 (1.44–10.00) | 0.46 | ||
| Left anterior descending artery | 3.25 ± 1.21 (1.48–7.37) | 3.66 ± 1.46 (1.26–9.36) | 0.10 | ||
|
| 0.45 | 0.86 | |||
| Myocardial region | |||||
| Septum | 3.27 ± 1.17 (1.19–6.97) | 3.68 ± 1.50 (1.15–8.84) | 0.10 | ||
| Inferior | 3.77 ± 1.54 (1.52–10.41) | 3.91 ± 1.80 (1.62–10.33) | 0.64 | ||
| Lateral | 3.51 ± 1.44 (1.63–9.87) | 3.64 ± 1.46 (1.36–9.47) | 0.61 | ||
| Anterior | 3.12 ± 1.28 (1.23–7.36) | 3.49 ± 1.48 (1.21–9.00) | 0.15 | ||
|
| 0.09 | 0.40 | |||
aMean CFR in whole left ventricle
MBF and CAD risk factors. Values are means ± SD
| Factor |
| MBF (ml·min−1·g−1) | CFR | |
|---|---|---|---|---|
| Baseline | Hyperaemic | |||
| Age (years) | ||||
| 31–49 | 41 | 1.06 ± 0.39 | 3.72 ± 1.46 | 3.75 ± 1.53 |
| 50–57 | 45 | 1.00 ± 0.34 | 3.63 ± 1.10 | 3.88 ± 1.45 |
| 58–83 | 42 | 0.99 ± 0.24 | 2.95 ± 0.84* | 3.07 ± 0.93 |
| | 0.58 | <0.01 | 0.01 | |
| Gender | ||||
| Men | 50 | 0.91 ± 0.34 | 2.90 ± 0.85 | 3.42 ± 1.24 |
| Women | 78 | 1.09 ± 0.30 | 3.78 ± 1.27 | 3.67 ± 1.45 |
| | <0.01 | <0.001 | 0.33 | |
| Hypertension | ||||
| Yes | 51 | 1.04 ± 0.34 | 3.31 ± 1.23 | 3.38 ± 1.46 |
| No | 77 | 1.00 ± 0.32 | 3.52 ± 1.18 | 3.70 ± 1.30 |
| | 0.15 | 0.30 | 0.09 | |
| Diabetes | ||||
| Yes | 21 | 1.03 ± 0.45 | 2.70 ± 0.61 | 2.80 ± 0.72 |
| No | 107 | 1.02 ± 0.30 | 3.58 ± 1.23 | 3.73 ± 1.42 |
| | 0.67 | <0.01 | <0.01 | |
| History of smoking | ||||
| Yes | 52 | 0.99 ± 0.21 | 3.50 ± 1.14 | 3.68 ± 1.40 |
| No | 76 | 1.04 ± 0.38 | 3.39 ± 1.24 | 3.50 ± 1.35 |
| | 0.84 | 0.47 | 0.54 | |
| Hypercholesterolaemia | ||||
| Yes | 37 | 1.01 ± 0.37 | 3.17 ± 1.26 | 3.33 ± 1.32 |
| No | 91 | 1.03 ± 0.31 | 3.55 ± 1.16 | 3.67 ± 1.39 |
| | 0.78 | 0.03 | 0.10 | |
| Family history | ||||
| Yes | 60 | 1.05 ± 0.35 | 3.55 ± 1.03 | 3.67 ± 1.45 |
| No | 68 | 1.00 ± 0.31 | 3.34 ± 1.33 | 3.49 ± 1.30 |
| | 0.52 | 0.13 | 0.51 | |
| BMI (kg·m−2) | ||||
| <25 | 43 | 1.06 ± 0.35 | 3.87 ± 1.29 | 3.86 ± 1.40 |
| 25–28 | 42 | 1.01 ± 0.38 | 3.37 ± 1.12 | 3.55 ± 1.19 |
| >28 | 43 | 0.97 ± 0.24 | 3.07 ± 1.05** | 3.32 ± 1.47 |
| | 0.50 | <0.01 | 0.19 | |
*p < 0.05, age band 31–49 vs. 50–57; **p < 0.01, vs. subjects with BMI <25 kg·m−2
Results of univariate and multivariate linear regression analysis of hyperaemic MBF and CFR
| Variable | Hyperaemic MBF | CFR | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
|
|
|
|
|
|
|
|
| |
| Age | −0.03 | <0.01 | −0.04 | <0.001 | −0.03 | <0.01 | −0.03 | 0.02 |
| Gender (male) | −0.88 | <0.001 | −0.94 | <0.001 | −0.25 | 0.33 | – | – |
| BMI | −0.08 | <0.01 | −0.07 | <0.01 | −0.06 | 0.03 | – | – |
| Diabetes mellitus type II | −0.88 | <0.01 | – | – | −0.92 | <0.01 | −0.80 | 0.01 |
| Hypertension | −0.22 | 0.32 | – | – | −0.32 | 0.20 | – | – |
| Hypercholesterolaemia | −0.38 | 0.10 | – | – | −0.34 | 0.21 | – | – |
| Smoking history | 0.11 | 0.61 | – | – | 0.18 | 0.47 | – | – |
| Family history of CAD | 0.20 | 0.34 | – | – | 0.18 | 0.47 | – | – |
Fig. 3Hyperaemic MBF in relation to gender, age and BMI. *p < 0.05